Table 1 Baseline characteristics.

From: Predictors of residual tricuspid regurgitation after interventional therapy: an automated deep-learning CT analysis

 

T-TEER (n = 32)

PA (n = 52)

p Value

Female, n (%)

19 (59)

34 (65)

0.579

Age, years (IQR)

82 (78–84)

81 (77–83)

0.287

BMI, kg/m2 (IQR)

24 (22–27)

25 (22–28)

0.235

EUROScore II (IQR)

5.6 (3.5–8.7)

4.5 (3.0–8.4)

0.261

NYHA class

0.112

 I, n (%)

0 (0)

0 (0)

 

 II, n (%)

2 (6)

8 (15)

 

 III, n (%)

25 (78)

40 (77)

 

 IV, n (%)

5 (16)

4 (8)

 

Leading cause of TR

0.131

 Primary TR, n (%)

1 (3)

1 (2)

 

 Atrial TR, n (%)

24 (75)

28 (54)

 

 Ventricular TR, n (%)

6 (19)

22 (42)

 

 CIED-related TR, n (%)

1 (3)

0 (0)

 

 Mixed pathology, n (%)

0 (0)

1 (2)

 

Coronary artery disease, n (%)

12 (38)

30 (58)

0.072

CIED, n (%)

11 (34)

14 (27)

0.468

Atrial fibrillation or flutter, n (%)

28 (88)

50 (96)

0.135

Arterial hypertension, n (%)

26 (81)

45 (87)

0.515

Diabetes mellitus, n (%)

4 (13)

16 (31)

0.082

Stroke, n (%)

8 (25)

9 (17)

0.394

Peripheral artery disease, n (%)

9 (28)

2 (4)

0.001

Chronic obstructive pulmonary disease, n (%)

9 (28)

9 (17)

0.241

History of surgical or percutaneous valve therapy, n (%)

14 (44)

18 (35)

0.402

Serum creatinine, mg/dl (IQR)

1.3 (1.0–1.7)

1.3 (1.0–1.4)

0.652

NT-proBNP, ng/l (IQR)

1919 (1062–3775)

2463 (1711–4206)

0.191

Bilirubin, mg/dl (IQR)

1.0 (0.6–1.6), n = 26

0.6 (0.5–1.1), n = 33

0.145

Systolic PAP, mmHg ± SD

38 ± 14, n = 23

41 ± 13, n = 24

0.521

Heart failure therapy

 Diuretics, n (%)

31 (97)

51 (98)

0.726

 Beta-blocker, n (%)

29 (91)

43 (83)

0.313

 ACE inhibitor or sacubitril/valsartan, n (%)

22 (69)

42 (81)

0.209

 Mineralocorticoid receptor antagonist, n (%)

20 (63)

31 (60)

0.793

 SGLT2 inhibitor, n (%)

13 (41)

10 (19)

0.033

  1. Continuous variables are shown as mean ± standard deviation (SD, normally distributed) or median with interquartile ranges (IQR, not normally distributed), categorical variables are given as absolute number with percentages. T-TEER, Tricuspid transcatheter edge-to-edge repair; PA, Percutaneous annuloplasty; BMI, Body mass index; EUROScore II; European System for Cardiac Operative Risk Evaluation II, NYHA class, New York Heart Association Class; TR, Tricuspid regurgitation; CIED, Cardiac implantable electronic device; NT-proBNP, N-Terminal pro brain natriuretic peptide; PAP, Pulmonary artery pressure; ACE, Angiotensin-converting enzyme; SGLT2, Sodium-Glucose Transport Protein 2.
Back to article page